Filters

Executive Dashboard

Headline pathway performance with red/amber/green alerting and prioritised next-best-actions.

Run scenario
Estimated SM patients identified
On track
1,683
2,000 in cohort
Median time to diagnosis
On track
220 d
symptom proxy → dx
Tryptase testing rate
Watch
47%
any biomarker test
KIT D816V testing rate
Watch
38%
confirmed KIT+ in cohort
Progression - 12 mo
Action needed
28%
progressing or progressed
Progression - 24 mo
Action needed
31%
subtype escalation observed
AdvSM patients on TKI
Watch
49%
targeted therapy initiated
High-priority HCP biomarker targets
On track
0
score ≥ 200
Care gaps detected
Action needed
7,926
6 critical rule(s) firing
Estimated patients missed or delayed
On track
317
undiagnosed or > 540 d to dx

Pathway funnel

Cohort flow from symptom proxy to therapy

Top care gaps

Ranked by severity then volume

  • No KIT D816V test on record
    1,056 patients · 52.8% · median delay 266d
    Critical
  • Recurrent anaphylaxis without epinephrine prescription
    755 patients · 37.8% · median delay 0d
    Critical
  • Elevated tryptase without hematology referral
    666 patients · 33.3% · median delay 90d
    Critical
  • No serum tryptase test on record
    575 patients · 28.8% · median delay 259d
    Critical
  • Recurrent anaphylaxis without tryptase testing
    306 patients · 15.3% · median delay 172d
    Critical
View all gaps

What should we do next?

Prioritised actions across HCPs, diagnostics, testing, medical affairs, and geography

Highest-impact HCP specialties

  • Gastroenterology
    382 patients · tryptase 42% · referral 38% · score 45
  • Rheumatology
    933 patients · tryptase 46% · referral 85% · score 28
  • Dermatology
    1,489 patients · tryptase 47% · referral 84% · score 27
Open HCP intelligence

Highest-impact diagnostic gaps

  • No KIT D816V test on record
    1,056 patients · median 266d delay · Order high-sensitivity KIT D816V from PB or BM.
  • Recurrent anaphylaxis without epinephrine prescription
    755 patients · median 0d delay · Dispense epinephrine auto-injector + action plan.
  • Elevated tryptase without hematology referral
    666 patients · median 90d delay · Direct hematology referral; bone marrow biopsy.
Open care gap engine

Highest-impact testing interventions

  • Reflex tryptase at allergy/immunology
    Cohort tryptase rate is 47%. Embed reflex order at recurrent anaphylaxis and idiopathic urticaria visits.
  • KIT D816V testing for suspected SM
    Only 38% have a KIT D816V result. Bundle KIT with elevated-tryptase reflex pathway.
  • AdvSM TKI initiation review
    49% of AdvSM patients on TKI. Trigger MDT review for untreated AdvSM.
Open biomarker opportunity

Highest-value medical affairs actions

  • Educate Gastroenterology
    Highest missed-opportunity score (45). Tryptase rate 42%, referral rate 38%.
  • Diagnostic checklist roll-out
    Distribute SM suspicion checklist to top-leakage HCPs identified in the biomarker opportunity module.
  • KOL engagement on progression monitoring
    Convene hematology KOLs on repeat tryptase / KIT cadence and AdvSM transition flagging.
Plan field activity

Highest-priority regions / institutions

  • Northeast
    499 patients · testing 45% · 276 untested
  • West
    502 patients · testing 46% · 271 untested
  • South
    512 patients · testing 50% · 257 untested
Drill into HCPs

Scenario to model first

  • National Patient Finder
    Combine high-sensitivity finder with HCP education to lift diagnosis rate at scale.
  • AdvSM TKI Optimisation
    Close the AdvSM-without-TKI gap with diagnostic finder + treatment initiation.
Open scenario simulator